Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398908 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL119530 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7532853 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL30291728 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL120255 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29867802 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1044856 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7420121 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29382791 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1000115 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111228508-B | Multi-target anti-tumor polypeptide drug conjugate and preparation method and application thereof | 暨南大学 | 2023-02-17 | — | — | CN | claimed |
| US-12622948-B2 | GLP-1/GIP dual agonists | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2026-05-12 | — | — | US | disclosed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4724472-A2 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724471-A1 | GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2026-04-15 | — | — | EP | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4482578-B1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2025-12-24 | — | — | EP | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114945579-A | Heme derivatives, their preparation and use | 吉林省澳宇生物科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114874293-A | Cyclic polypeptide compounds and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022079639-A1 | GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022064500-A1 | METHODS FOR ULTRAFAST FORMATION OF DISULFIDE BONDS IN PEPTIDES AND PROTEINS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-114053398-A | New medicinal application of heme polypeptide derivative | 吉林省澳宇生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | TLR2 644/4885MDM4 2209/4885TP53 300/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | TLR2 213/4885MDM4 3040/4885TP53 421/4885 |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | TLR2 729/4885MDM4 4874/4885TP53 2182/4885 |
| US-12622948-B2 | GLP-1/GIP dual agonists | GLP1R, GIPR, NPY4R | TLR2 2282/4885MDM4 4857/4885TP53 4808/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | TLR2 121/4885MDM4 1128/4885TP53 158/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | TLR2 3196/4885MDM4 1577/4885TP53 11/4885 |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | GIPR, NPY2R, NPY1R | TLR2 874/4885MDM4 4186/4885TP53 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.